Arcturus Therapeutics Holdings Inc [ARCT] stock is trading at $19.23, up 0.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ARCT shares have gain 60.52% over the last week, with a monthly amount glided 49.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] stock has seen the most recent analyst activity on May 28, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $32. Previously, BTIG Research started tracking the stock with Buy rating on January 28, 2025, and set its price target to $41. On August 12, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $70 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $90 on December 13, 2023. William Blair initiated its recommendation with a Outperform and recommended $71 as its price target on July 24, 2023. H.C. Wainwright upgraded its rating to Buy for this stock on May 11, 2023, and upped its price target to $51.
Arcturus Therapeutics Holdings Inc [ARCT] stock has fluctuated between $8.04 and $25.88 over the past year. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $19.23 at the most recent close of the market. An investor can expect a potential return of 108.01% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] reported sales of 109.80M for the trailing twelve months, which represents a drop of -46.69%. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -0.62%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.61 points at the first support level, and at 17.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.92, and for the 2nd resistance point, it is at 20.61.
Ratios To Look Out For
For context, Arcturus Therapeutics Holdings Inc’s Current Ratio is 5.90. As well, the Quick Ratio is 5.90, while the Cash Ratio is 4.22. Considering the valuation of this stock, the price to sales ratio is 4.76, the price to book ratio is 2.26.
Transactions by insiders
Recent insider trading involved Chivukula Pad, Chief Scientific Officer & COO, that happened on Oct 15 ’24 when 12000.0 shares were sold. Officer, Chivukula Pad completed a deal on Oct 15 ’24 to buy 12000.0 shares.
